Analytical Data
-
Gene name
CCR5
- Application
-
Alternative Names
CD195; CC-CKR5; CCCKR5; CMKBR5; CHEMR13; HIV-1 fusion coreceptor
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
P51681
-
Expression Region
Glu302~Leu352
-
Molecular Weight
13/15kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CCR5 (C-C chemokine receptor type 5) is a crucial protein functioning as a co-receptor for HIV-1 entry into host cells, facilitating viral fusion and infection. Its role in the immune system, particularly in the inflammatory response, has made it a significant target for therapeutic interventions in HIV treatment and potential vaccines. Researchers have been investigating CCR5 for its involvement in various other diseases, including cancer and autoimmune disorders, due to its impact on cell signaling and migration. The development of CCR5 antagonists, such as maraviroc, heralded a new class of antiviral drugs, enhancing the understanding of how blocking this receptor could lead to better management of HIV. Moreover, genetic studies have identified mutations like CCR5-Δ32 that confer resistance to HIV infection, sparking interest in gene therapy approaches. In recent years, recombinant protein technologies have enabled the production of CCR5 protein for structural and functional studies, paving the way for innovative research in drug design and therapeutic applications. Understanding the precise mechanisms of CCR5 interactions at a molecular level continues to be of great importance, aiming to exploit its pathways not only for combating HIV but also for broader applications in treating related conditions, thereby advancing both virology and immunology fields.
